Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Bavarian Nordic clinical trials
Also known as BN.
The registry lists 58 studies whose lead sponsor is Bavarian Nordic. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Keep track of what changes. Save the Bavarian Nordic studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Bavarian Nordic.
- Bavarian Nordic58 studiesSame company
Something wrong?
Focus areas
Conditions Bavarian Nordic leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 58. Browse all 58 →
- Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young AdultsNot yet recruitingNCT07888088Phase 1
- An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and AdultsRecruitingNCT07467707Phase 3
- A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.Active, not recruitingNCT07003984Phase 3
- Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster VaccinationActive, not recruitingNCT06007183Phase 3
- Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production CellsActive, not recruitingNCT07199569Phase 2
- Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus InfectionsActive, not recruitingNCT06549530Phase 2
- A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV VaccineActive, not recruitingNCT06899802Phase 2
- TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing CancerCompletedNCT04246671Phase 1
- ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2CompletedNCT05329220Phase 3
- Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 YearsCompletedNCT05349617Phase 3
- MVA-BN-RSV Vaccine TrialTerminatedNCT05238025Phase 3
- Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)CompletedNCT03992872Phase 2
- ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult SubjectsCompletedNCT05077267Phase 2
- A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)CompletedNCT05072080Phase 3
- Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy AdultsCompletedNCT04752644Phase 2
- Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among TravelersCompletedNCT02391909
- A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle VaccineCompletedNCT05065983Phase 2
- Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy AdultsCompletedNCT03483961Phase 2
- A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older AdultsCompletedNCT02100631Phase 3
- A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy AdultsCompletedNCT02094586Phase 3
- Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent CholeraCompletedNCT01895855Phase 3
- VAXCHORA Pediatric Study to Assess Safety and ImmunogenicityCompletedNCT03220737Phase 4
- Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200CompletedNCT01585181Phase 1
- BN Brachyury and Radiation in ChordomaCompletedNCT03595228Phase 2
- CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedNCT03628716Phase 2
- A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced CancerCompletedNCT04134312Phase 1
- Freeze-Dried MVA-BN® Lot Consistency Smallpox TrialCompletedNCT03699124Phase 3
- A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy SubjectsCompletedNCT01668537Phase 2
- RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old AdultsCompletedNCT02873286Phase 2
- Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)CompletedNCT03349983Phase 1
- Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult SubjectsCompletedNCT04131595Phase 1
- Special Access Program IMVAMUNE®CompletedNCT03472014Phase 4
- Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV InfectionCompletedNCT02038881Phase 2
- A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung CancerCompletedNCT02840994Phase 1
- A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®CompletedNCT01913353Phase 3
- A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate CancerCompletedNCT01322490Phase 3
- A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant TherapyCompletedNCT01152398Phase 1
- A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast CancerCompletedNCT00485277Phase 1
- An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 VaccineesCompletedNCT00686582Phase 2
- A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate CancerCompletedNCT00629057Phase 1
- A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy SubjectsCompletedNCT00316524Phase 2
- Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic DisordersCompletedNCT00189917Phase 1
- Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.CompletedNCT00189956Phase 2
- A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced SubjectsCompletedNCT00857493Phase 2
- A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic DermatitisCompletedNCT00316602Phase 2
- Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected PatientsCompletedNCT00316589Phase 2
- A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve SubjectsCompletedNCT01144637Phase 3
- RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.WithdrawnNCT02864628Phase 1
- PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone TherapyCompletedNCT00078585Phase 2
- Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV VaccineCompletedNCT02419391Phase 1